> >>?> @ >> @ 44 40 > <89? < @? <20 @?@> Original Article?> @?>? @>@? @ @>??> 4 > >@? 4 3 2 <? > <? < @ >@ < @ 6 5 >?? <? @ @ >> < @? < @??> > < E @> > @ >> 2 @ @ >> < @? < @??> > <?? > @> > @ >> 3 @ @ >> < @? < @??> > <?@ @ @> > < @ @ @ >> < @? < @??> > <?? > @> > < @ 5 @? < @??> > < @ @ >> <? > > 6 @? < @??> > < @ @ >> <> >?> @ >?@. > @?> @> @ > @? @>@? @ 4 @ :@ @ @>??> 4 > @> @? < > @ >?> @. > >>?> @? @? @? > @ >.>?> @?>? @>@? @? 60 @?>? @>@? @? 6 2 < -?> :??@? @> > @> @? @??> > 383-387 @ @ >. Log rank @?> @ >?@> @?@??> @> > @>>> @? > () @>?>?.? < >. >? @ >?> @> > @>? > >? @ 82/5?>? > >?> > @> > <> @?>> @ > @>?>>?> @?> @@ @> 4 > :?>??>?> @ @>??>. (p=0/044)?> 56/4 >>? > @@?> @ >?>.(p=0/038) (%95CI=/06-8/) 2/93? @>?> >>? > @>.> >> >?> > @> >>> @ >. >? >?> < > @ :@. > >>? >? @?>? @>@??> @. @ <()?>? @>@? @ <?>? @>@? @ <> :@ @ E>@?. @>>> @ >?> >? 46?>.() @ > @ @? @?> @ @> >?> @ >??> @ (0000?> 7) @ >? @ 5000 @ @> @ > @> > > >?>?@ @? >? >.> > @ 680 @ @? 450 @ 30 <384 @?>.(2) > @ > @ @?> @ @ @ @>? @>@? @ 300 >@ @ @ @. @ >?>? @?> @ @ < @??> > < @ @ >> <@> :@ @??>> (email: mah_haghighi@hotmail.com) 388/3/20 :?>? 388/7/30 :??
4 /@>? @ @ @? @ >> >?@ @?> @ >? @ < @ - @ >?> > @ @ @ @? 387 >?@ 383 @ @ > @> @ @ > @ @ @? @ @??> @ @ @ @ @ @ @? @ @ >@?> > > > @ @ @ @ @ @ > @ > > @ >?>. @ > > 2?>.? <> >?> @ @ > Bethesda @ @ @ @ >@ 60 <>> > @ @ 6 @?>?>? @>@? @ @@ @?> @?> < @ > >? @ @ @ >.? @ @>@? @ @ >> > @? @ @@ > @@ > @> @@ @ @@ @@?> () @@?> @ >. @ @> @ > 2002 @ @?> (Bethesda guidelines) :?>?. @ 50?>. @ > @?> @? @?? >.2 60?> @@ (MSI-H). >>? @ @?> @@ @ @@??> @?> @@.3. >>?> @ @@> @?> @ @ @?> @ > @.4. >? > @>> @ @ @ @ > @ @>?> @ @ @ > @ @> > @.5?> @@ @? @? @>@? @.() >? > @> > @?> @ > @ @ < @?>? @ @ @> @ > @ @ @ >??>?>? >? >> >. @ @?> >>? > >?> @> > < < @ < @ @ @??>??> >? @. @ > > @? @? @ <@??> @ @ @> @ @ @? @> > @>?.? @>@? @ @?> @? >> > @? >?>?> @? > >.> @?> @ >> > @ @ @ @ @ @?> @ @ @ @ @ >? @ @>? @ > @ @ @>? > @?. > @ @@?@??> @> @@ > @@ > @@ @ @@ @@. @@ >? @ Log-Rank @?> @? (Kaplan-Meier) > @>. @ > > @> 89? @? 20 @?@> @ > < @ > @>>> @ >?> @> > > >>??@ @? >? >?> 8/ @> >?@ @> @> >?>> @ @ @ @ @ @?> @?> 7/5 @?> @?> @>?@ @ <> @ @ @ > @. @? @ @>>?> @? @>@? @ >.(3) > > > @> > @> >. > > @> @? @.> @ @ @?> @?>? @> @ >? @@@@@ @> @@@@@ > @@@@@ @@@@@ @@@@@ @@@@@?> (Hereidatary Non Polyposis Colorectal FAP (Familial Adenomatous Polyposis) @ Cancer) 20 @ @ @ @?> >?> @ @?> 80 @. @?> 5-0 <@ @ @ >?> @?> @?>.(4) >??> @ @? @ < @ > >?> @ >? < @ @?> < @>) @??> @? @?@ @ >?> @?>?> 2/6 (? @ > > < @?>. @ > @@? @??> @>?> 4/ @ @>>?>? > @?@ >?>?>?> 7/9 @?> 7/7 >?>.(5) > @ > @? @ @>>?> @ @ @ @ @ @ <>?> @??> @ @ @ @ > @. @ >@>>> @ >? @> > @ @ @ @? > @>>> @ > @? <@? > @ @?.(6<7) >?>>? @?? >?> @ > @ >? @ Henry Lynch > <996 @?> @> @ @ > @ > @ @ @? @>? @>@? @ @ > @ @ @ @ @ @.(8) @ @ @ @? >? @>@? @??> @ >. > Lynch @? >? @? @?>? @>@? @ >? @ <> >?.> @ @ @ @ > @ @> @? >> @ @>?> FAP.> @ @?> >?? @ @>@? @ @ @ @ @ @?> 5-0 > @ @ @ > @ <>?>> @ @E @ @>? @ @ @ @ @ @?> @ @ @? >?>@ @ >.(9<0). > > @ @ @ > @ @ @ @ > @> @ >? > @>? @?> > @ @ @ @>??> > @> @ > >@ @? @>@? @?>? =
?> @?>? @>@? @ @>??> 4 > > @ @> @ >@?> @?>? @>@? @.(2 @@ ) >?>> > @ @> > @ @>? > @? - @@ p-value (?>) >> > @? 0/43 ( 49/6) 60 > ( 50/4) 6 @? @? 0/298 ( 65/3) 79 < 50 ( 22/3) 27 64-50 ( 2/4) 5 > 65 @??> 0/64 ( 7/3) 2 ( 30/6) 37 ( 52/) 63 >? @ 0/845 ( 76/9) 93 @ ( 23/) 28 @? @? 0/044 ( 50/4) 6 >>? > ( 49/6) 60 @ @ @ @ @>? @?> @ > @? -2 @@ @?> @> > @? p-value > @? * 0/064 (0/94-9/90) 3/ 04 @??> 0/5 ( 0/47-4/57) / 46 -- > @? 0/038 ( /06-8/) 2/ 93 >>? > -- * %95 @> @> > >> >> > Cox?> @ > >>?> @ >> @ /42 ) @@ @ @@? @ @@?> @ @@ > @@ > @@ (P-value) @ @ >?>. @> > (Regression @ > > @?>?>> @> 0/05. 3 > @ SPSS?> @>? @.???> >@?> @> > 2 >?> (@ @ 78-22 @ >> @ ) @ @ 47/25±2/9 @ @ @? @@ @@ @>? @@ @ @@. @@ > @@ @> @@ @ @@ 53/59 ±4/35 @@?> @ @@ 44/33±0/74 @ > @ > @ @?>? @ @>@? @ @ @ @ @>? >> @ > @ > > >?>> >@ > >.(P=0/008) @ @ > @ > > @ @>? @?>.> @ @ @ 50 @? >> @ > @ @? @ > @ >?> < @ > @ @?>? @ @>?>> (?> 85) 5 < @ 42 @?> @ @? @ @ @ >> >?> @ >.(P=0/035) @ >>? @ @ @?> ( @?> 68/9) @ @>? @ > @>?> >? @?>> >@ @?> @?>> @ >@ @ @.(?>> ) >>> @ >>? > @ @? @ @ @?> < @? @ < @.( @@ ) @ > @@??> > @>?>? @ @ @ @> @? @>@? @?> @ @ > >? @. >? @ @ @>>> > >.> > >? @>@? @ @> @ > @?> @ @ @ > @ @>? > @> > >. >?>? >? @?? > ( @ ) @ -?>> @? @ @ >?> @>?>> @?@??> @.(2) @ @? @ >?>@ < > 0/25?> @?> <>?> @ > @??>?> @ >>> @
43 /@>? @ @ 89? @? 20 @?@> @ @ @>? @ >>> @ > > @@ @ > @ @ @ @ > @>?>>?> @ @ @ > @> @>??> @ @>?> @ > @ <>?>> < @ > >?> @ >>? > >?>?> >? > @> @ >.(8) > @ @ >> > >?>? @ > @?> @ @ @ @ > @ @ >> >> > @ @ @ > @ @ @> @ @ < >@> @? @ > @ @??@?> > <?@?> > >?> @?> @ @ @ @ @ @?> @ > @?. > >?> > @>?> @ @> @ @> @ @ @ > > > >> @ > @ @ @?>? @ @>@? @ @ >> >?> >?> @ @??>? @>@? @?> @ @ @ @ >> @ >?> > @ > @ > @> @ @ >? @ > @ @ @ > >? @>@? @ >? > @ @ E @ @ @?@ @ @ @? @?> @ @ >.? @>@? @ @ @? 77 @>> @?> @ 78/4 @ @??> @ 3/5 > @ < @ @ >?> @ @ > @ @ @ @?>> @ > @ @ @@ @?> @ @ @ @ @ >.(NS) @ < @ >?? < > @ @ > > >?> @>? @ > > @ > @ @ @ @?>>??> > @?.(9) @ @ @ @ @> @ @.> >@ @>?>> > @ > @ @?>? @ @ @>? @ @ > @ >?> @ @>? @ @ @?> @ @>?> >? >? < > @ > @ @>? @> > @?> > @ @ > @ @. @ @?> @ @ @? @?@> @?>?> @ @ > @>? @ > @ @ @ > @ >? @??>. >? >?> < @ @? >>? @ >> @ > @>??> > @ @. >>? @ @? DNA @ @?> @ >? > > E > <> @ @ @ @ > @ >@ @ @ >. @ > >@ @ >>? @ >. > E >> @ @? >@ > @ @ @>? @ @ 4 > @ @ >>> @ @ > > @ (%56/4) >>? @ > >?>?> (?> 82/5) @> @ @ >? @ @ @> @ >.(P=0/044) @> @ @ >>> @?> @>?. > @> @ @ @?> 65 @>? @ @> @ @ @ 5 > @ @ @ >? > > @ @ >?> 44 >>? > @>? < @ @ @ > @?> @ > @> @@.(3) >>>?> @ @ @>? @?> @ > @ @ >>> @ @ @@ > @@.(4) @@ > @@ >>? @@ > @>? @@ @@ @@ @ > @ <>>> @ @ >? @ @ @ @>?> @> @ > @ @> @ @ @?> 55/2 @> 5 > @> @ @ @> @ @ @ @ @ >?> 42/5 >>? >.(5) > >@ @?> > @?> @ >? @>? @ >@ @ @?>? < >?>.>?> @ @? @ @ @ @ >??> >@ >.> @. > @ > @ @> (Grad of Tumor)??>?> @ @ @ @ @ > @?> > @> @.>?> @ > @>? @ > @ @ @ @? @?> > >?>> @ @ > > @?> @ @ >.>?> @ @? @?> @ @>>> @ >?>?>.(6) @ @ @ @ @ >. > >> > > @@? @ @ > >? @??> >>> @ @ @ >. @? @>@? @ @>? @> @??> @?.>?>> > >?> < @ @ @ > @ @ >>??> >?> > @?> @? @ @ @?> @ @ @>>> @ @ @@ @ @? @?> @ @ > @@?> @ @ @ @@@ @ @ > @?> @ @?> <>?>> @? @ > > @? >> @ @? @ @> @ >.(7) > >??>?> @ @ @>>> REFERENCES. Aaltonen LA, Salovaara R, Kristo P. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 998; 338: 48 87.
?> @?>? @>@? @ @>??> 4 > > >>?> @ >> @ /44 2. Islamic Republic of Iran, Ministry of Health and Medical Education, Office of Deputy Minister for Health Center for Disease Control, Cancer Office. Iranian annual national cancer registration report, 2005 2006. Tehran: Iranian Center for Disease Control; 2006. 3. Cancer Office of Deputy Minister for Health Center for disease control, Ministry of Health and Medical Education, Islamic Republic of Iran. Iranian annual national cancer registration report, 2005: Tehran: Iranian Center for Disease Control; 2007. 4. Naccarati A, Pardini B, Hemminki K, Vodicka P. Sporadic colorectal cancer and individual susceptibility: a review of the association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res 2007; 635: 8 45. 5. Boyle P, Langman JS. ABC of colorectal cancer. Epidemiology. BMJ 2000; 32: 805-808. 6. Roncucci L, Fante R, Losi L, Di Gregorio C, Micheli A, Benatti P, et al. Survival for colon and rectal cancer in a population based cancer registry. Eur J Cancer 995; 32A: 295. 7. Marie RG, Erik JB, Robert JC, Robert WB, Josep LM. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 987; 60: 238. 8. Nishisho I, Nakamura Y, Miyosshi Y. Mutation of chromosome 5q2 genes in FAP and colorectal cancer patients. Science 99; 253: 665 69. 9. Lynch HT, Smyrk TC, Watson P. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposiscolorectal cancer: an updated review. Gastroenterology 993; 04: 535 49. 0. Lynch HT, Smirk TC. Hereditary nonpolyposis colorectal cancer (Lynch syndrome): updated review. Cancer 996; 78: 49 67.. Piñol V, Castells A, Andreu M, Castellví-Bel S, Alenda C, Llor X, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293: 2028-30. 2. Kleinbaum D, Kupper L, eds. Applied regression analysis another multivariable methods. st edition. Boston: Duxburg; 978. p.88 209. 3. Sankila R, Aaltonen LA, Jarvinen HJ. Better survival rates in patients with MLH-associated hereditary colorectal cancer. Gastroenterology 996; 0: 682-87. 4. Elsakov P, K Urtinaitis J. Survival from colorectal carcinoma in families as compared to the general population in Lithuania-initial results. Fam Cancer 2006; 5: 369-7. 5. Percesepe A, Benatti P, Roncucci L. Survival analysis in families affected by hereditary non polyposis colorectal cancer. Int J Cancer 997; 7: 373-76. 6. Chapuis PH, Dent OF, Fisher R, Newland RC, Pheils MT, Smyth E, et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 985; 72: 698. 7. Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in,38 Iranian colorectal cancer patients. Int J Colorectal Dis 2008 ; 7: 683-88. 8. Aarnio M, Mecklin JP, Aaltonen LA. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer () syndrome. Int J Cancer 995; 64: 430 33. 9. Hosseninasab AR, Modir Abbas, Shir yazdi SM. Survival analysis of colorectal cancers, Yazd, 98-2000. Journal of Shahid Sadoughi University of Medical Science 2002; 9: 23-29. [In Persian]